LUX-Lung IO: A Phase II, Open Label, Non-randomised Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Keynote 497; LUX-Lung IO
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 27 Nov 2017 Planned End Date changed from 19 Feb 2021 to 25 Feb 2021.
- 03 Nov 2017 Status changed from not yet recruiting to recruiting.
- 18 Oct 2017 Planned initiation date changed from 16 Oct 2017 to 2 Nov 2017.